Issue Date: February 21, 2011
Evotec Buys Kinaxo, Works With ChemBridge
The German contract research organization Evotec has acquired Kinaxo, a Munich-based company that offers technologies for response prediction and safety assessment in drug development. Evotec will pay about $16 million and could make $5 million in additional payments depending on Kinaxo’s performance. Separately, Evotec will work with ChemBridge to expand its screening library. Evotec will enhance its library of 250,000 druglike compounds with an initial 110,000 compounds from ChemBridge.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society